"Nothing to lose and the possibility of gaining": a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
07 Feb 2023
Historique:
received: 14 04 2022
accepted: 20 01 2023
entrez: 7 2 2023
pubmed: 8 2 2023
medline: 9 2 2023
Statut: epublish

Résumé

Randomised controlled trials (RCTs) are considered the "gold standard" for evaluating the effectiveness of interventions in clinical research. However, conventional RCTs are typically complex, expensive, and have narrow eligibility criteria, which limits generalisability. Registry-based randomised controlled trials (RRCTs) are an alternative approach that integrates the internal validity of an RCT with the external validity of a clinical registry by recruiting real-world patients and leveraging an existing registry platform for data collection. As RRCT is a novel research design, there has been limited research on the feasibility and acceptability of RRCTs from the patients' and trial team's perspectives. This study aims to explore patients', clinicians', and study coordinators' perspectives towards participation in and conduct of oncology RRCTs in Australia. Thirty-seven semi-structured interviews were conducted with 15 cancer patients, 15 clinicians, and 7 study coordinators. Interviews were audio-recorded and transcribed verbatim. The data were analysed using thematic analysis. Three overarching themes were identified: (1) enablers and barriers to recruitment and enrolment of patients in RRCTs, (2) experiences of patients participating in RRCTs, and (3) recommendations for the implementation of future RRCTs. For patients, altruism and "trust in the clinician" were key reasons to participate in a RRCT. For clinicians and clinical trial coordinators, the RRCT study design was perceived as "simple and straightforward" but "less exciting" than RCTs. Competition from commercially sponsored RCTs poses challenges for investigator-led RRCTs recruitment, particularly if eligible patient numbers are low. There were limited impacts on patients' treatment experiences and clinicians' clinical workflow given that the RRCTs explored different standards of care. Recommendations to improve the enrolment of patients in RRCTs included generating greater buy-in from clinicians by increasing awareness of RRCTs via education initiatives and broader promotion of the "selling point" of RRCTs and providing monetary compensation to hospitals for enrolling patients. Whilst patients, clinicians, and study coordinators were generally supportive of RRCTs, several barriers to effective RRCT implementation in oncology were identified. Developing strategies to increase acceptance of the methodology by clinicians will help enhance the uptake of RRCTs in Australia and internationally.

Sections du résumé

BACKGROUND BACKGROUND
Randomised controlled trials (RCTs) are considered the "gold standard" for evaluating the effectiveness of interventions in clinical research. However, conventional RCTs are typically complex, expensive, and have narrow eligibility criteria, which limits generalisability. Registry-based randomised controlled trials (RRCTs) are an alternative approach that integrates the internal validity of an RCT with the external validity of a clinical registry by recruiting real-world patients and leveraging an existing registry platform for data collection. As RRCT is a novel research design, there has been limited research on the feasibility and acceptability of RRCTs from the patients' and trial team's perspectives. This study aims to explore patients', clinicians', and study coordinators' perspectives towards participation in and conduct of oncology RRCTs in Australia.
METHODS METHODS
Thirty-seven semi-structured interviews were conducted with 15 cancer patients, 15 clinicians, and 7 study coordinators. Interviews were audio-recorded and transcribed verbatim. The data were analysed using thematic analysis.
RESULTS RESULTS
Three overarching themes were identified: (1) enablers and barriers to recruitment and enrolment of patients in RRCTs, (2) experiences of patients participating in RRCTs, and (3) recommendations for the implementation of future RRCTs. For patients, altruism and "trust in the clinician" were key reasons to participate in a RRCT. For clinicians and clinical trial coordinators, the RRCT study design was perceived as "simple and straightforward" but "less exciting" than RCTs. Competition from commercially sponsored RCTs poses challenges for investigator-led RRCTs recruitment, particularly if eligible patient numbers are low. There were limited impacts on patients' treatment experiences and clinicians' clinical workflow given that the RRCTs explored different standards of care. Recommendations to improve the enrolment of patients in RRCTs included generating greater buy-in from clinicians by increasing awareness of RRCTs via education initiatives and broader promotion of the "selling point" of RRCTs and providing monetary compensation to hospitals for enrolling patients.
CONCLUSIONS CONCLUSIONS
Whilst patients, clinicians, and study coordinators were generally supportive of RRCTs, several barriers to effective RRCT implementation in oncology were identified. Developing strategies to increase acceptance of the methodology by clinicians will help enhance the uptake of RRCTs in Australia and internationally.

Identifiants

pubmed: 36747274
doi: 10.1186/s13063-023-07109-2
pii: 10.1186/s13063-023-07109-2
pmc: PMC9902247
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

92

Informations de copyright

© 2023. The Author(s).

Références

J Surg Res. 2020 Nov;255:428-435
pubmed: 32619857
Trials. 2021 Nov 25;22(1):844
pubmed: 34823582
Am Heart J. 2010 Dec;160(6):1042-8
pubmed: 21146656
Asia Pac J Clin Oncol. 2019 Jun;15(3):188-189
pubmed: 30747499
J Clin Nurs. 2019 Jul;28(13-14):2443-2461
pubmed: 30673153
Br J Cancer. 2013 Apr 16;108(7):1402-7
pubmed: 23511558
Learn Health Syst. 2020 Jan 13;4(3):e10211
pubmed: 32685681
JACC Cardiovasc Interv. 2014 Aug;7(8):857-67
pubmed: 25147030
Trials. 2021 Sep 6;22(1):597
pubmed: 34488851
Eur J Endocrinol. 2021 Feb;184(2):R51-R59
pubmed: 33166271
Eur Urol. 2017 Nov;72(5):789-798
pubmed: 28578829
Asia Pac J Clin Oncol. 2022 Aug;18(4):344-352
pubmed: 34811922
BMC Geriatr. 2020 Jan 21;20(1):19
pubmed: 31964340
Diabetologia. 2022 Oct;65(10):1575-1586
pubmed: 35902386
Trials. 2018 Aug 4;19(1):419
pubmed: 30075741
Trials. 2020 Jun 22;21(1):552
pubmed: 32571382
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Cancer Control. 2018 Jan-Mar;25(1):1073274818765475
pubmed: 29592528
Asia Pac J Clin Oncol. 2018 Dec;14(6):365-373
pubmed: 29947051
J Clin Epidemiol. 2016 Dec;80:16-24
pubmed: 27555082
Acta Orthop. 2020 Oct;91(5):506-513
pubmed: 32567472
Nat Rev Cardiol. 2015 May;12(5):312-6
pubmed: 25781411
Br J Clin Pharmacol. 2018 Jun;84(6):1384-1388
pubmed: 29446851
Asia Pac J Clin Oncol. 2019 Jun;15(3):186-187
pubmed: 30747483

Auteurs

Khic-Houy Prang (KH)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia. khic-houy.prang@unimelb.edu.au.

Bill Karanatsios (B)

Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.
Western Health Chronic Disease Alliance, Western Health, St Albans, VIC, Australia.

Angela Zhang (A)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.

Ebony Verbunt (E)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.

Hui-Li Wong (HL)

Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Vanessa Wong (V)

Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia.

Lucy Gately (L)

Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.

Ben Tran (B)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Peter Gibbs (P)

Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
Department of Medical Oncology, Western Health, Sunshine, VIC, Australia.

Margaret Kelaher (M)

Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH